Field Medical Company Profile

Background

Field Medical, established in 2022 and headquartered in Cardiff-by-the-Sea, California, is a medical device company specializing in the development of pulsed field ablation (PFA) technologies. The company's mission is to revolutionize cardiac ablation treatments by enhancing efficacy and minimizing unintended consequences associated with traditional methods.

Key Strategic Focus

Field Medical is dedicated to pioneering the next generation of PFA technology, aiming to address unmet needs in arrhythmia care. The company's core objectives include:

Development of the FieldForce™ Ablation System: A cutting-edge PFA system designed for the treatment of ventricular tachycardia.

Advancement of PFA Technology: Utilizing micro-bursts of energy delivered via catheter to disrupt cardiac cells without the heat or cold signatures associated with conventional ablation procedures.

Financials and Funding

Field Medical has raised a total of $14 million in funding over one round. The company is actively seeking additional partnerships to further its development efforts.

Pipeline Development

The company's flagship product, the FieldForce™ Ablation System, has achieved significant milestones:

FDA TAP Pilot Acceptance: Recognized under the Total Product Life Cycle Advisory Program.

Breakthrough Device Designation: Granted by the FDA for the treatment of ventricular tachycardia.

Technological Platform and Innovation

Field Medical's innovation centers around its proprietary PFA technology, which offers several advantages over traditional ablation methods:

Micro-Burst Energy Delivery: Utilizes rapid, targeted energy bursts to disrupt cardiac cells.

Minimized Thermal Impact: Eliminates the heat or cold signatures that can lead to collateral tissue damage in conventional procedures.

Leadership Team

Dr. Steven Mickelsen: Chief Executive Officer. Dr. Mickelsen leads the company's strategic vision and development efforts.

Quyen N.: Director of Engineering. Oversees the engineering team and product development initiatives.

Bart Schade: Vice President of Operations. Manages operational strategies and processes.

Michelle Kennefick: Vice President of Clinical Affairs. Leads clinical research and regulatory affairs.

David Jacques: Senior Vice President of Product Development. Directs product innovation and development strategies.

Oskar Marus D.: Chief Financial Officer. Oversees financial planning and management.

Marlou Janssen: Member of the Board. Provides strategic guidance and oversight.

Competitor Profile

Market Insights and Dynamics

The cardiac ablation market is experiencing significant growth, driven by the increasing prevalence of arrhythmias and advancements in ablation technologies. PFA is emerging as a promising alternative to traditional thermal ablation methods, offering improved safety and efficacy profiles.

Competitor Analysis

Key competitors in the PFA and broader cardiac ablation market include:

Medtronic: A global leader in medical technology, offering a range of cardiac ablation products.

Biosense Webster (a subsidiary of Johnson & Johnson): Specializes in electrophysiology products, including advanced ablation catheters.

Acutus Medical: Focuses on electrophysiology mapping and ablation technologies.

Farapulse (acquired by Boston Scientific): Develops PFA systems for cardiac ablation.

Strategic Collaborations and Partnerships

Field Medical is actively seeking strategic partnerships to enhance its market position and innovation capacity. The company is open to collaborations that align with its mission to revolutionize cardiac ablation treatments.

Operational Insights

Field Medical differentiates itself through its focus on PFA technology, aiming to provide safer and more effective treatments for arrhythmias. The company's commitment to innovation and patient-centric solutions positions it competitively in the evolving cardiac ablation market.